Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.03−0.30 (-22.56%)
Close on Nov 18, 2026Market cap $96.53MP/E –Yield –
Innate Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€54.01M. The highest annual figure on record is €5.15M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€54.01M | – |
| FY2024 | Dec 31, 2024 | -€51.58M | – |
| FY2023 | Dec 31, 2023 | -€12.67M | – |
| FY2022 | Dec 31, 2022 | -€57.43M | – |
| FY2021 | Dec 31, 2021 | -€47.83M | -4532.3% |
| FY2020 | Dec 31, 2020 | €1.08M | -31.5% |
| FY2019 | Dec 31, 2019 | €1.58M | -69.4% |
| FY2018 | Dec 31, 2018 | €5.15M | – |
| FY2017 | Dec 31, 2017 | -€39.98M | – |
See a number that looks wrong?